<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576301</url>
  </required_header>
  <id_info>
    <org_study_id>OX1222</org_study_id>
    <nct_id>NCT02576301</nct_id>
  </id_info>
  <brief_title>Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS</brief_title>
  <acronym>AML</acronym>
  <official_title>Ph 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination With Cytarabine With Subsequent Phase 2 Cohorts for Subjects With Relapsed/Refractory Acute AML and MDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mateon Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mateon Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 will investigate maximum tolerated dose of OXi4503 as a single agent and in
      combination with intermediate-dose cytarabine in subjects with relapsed/refractory AML or
      MDS.

      Phase 2 will investigate overall response rate of OXi4503 in combination with
      intermediate-dose cytarabine in 1) subjects with MDS after failure of 1 prior hypomethylating
      agent (Arm A) and 2) subjects with relapsed and refractory AML after treatment failure of up
      to 1 prior chemotherapy regimen (Arm B).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 dose escalation component will assess the safety, PK/PD, and preliminary efficacy of
      OXi4503 as a single agent in subjects with relapsed/refractory AML and MDS, and the safety
      and PK/PD of the combination of OXi4503 with intermediate-dose cytarabine in subjects with
      AML/MDS.

      Phase 2 will assess the preliminary efficacy of the OXi4503+cytarabine combination in 2
      cohorts.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b:MTD of OXi4503 as a single agent and in combination with intermediate-dose cytarabine in subjects with relapsed/refractory AML or MDS</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Overall response rate of OXi4503 in combination with intermediate-dose cytarabine in subjects with MDS after failure of 1 prior hypomethylating agent (Arm A), and subjects with relapsed and refractory AML after treatment failure of up</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Phase 2 AML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OXi4503 at MTD plus cytarabine 1g/m2/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 MDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OXi4503 at MTD plus cytarabine 1g/m2/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OXi4503 dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTD for OXi4503 will be determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OXi4503 + cytarabine dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTD of the combination of OXi4503 + cytarbine will be determined</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase 1 - OXi4503</intervention_name>
    <description>Determination of MTD of OXi4503</description>
    <arm_group_label>OXi4503 dose escalation</arm_group_label>
    <other_name>CA1P</other_name>
    <other_name>combretastatin A1-diphosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase 1 - OXi4503 + cytarabine</intervention_name>
    <description>Determination of MTD of the combination of OXi4503 + cytarabine</description>
    <arm_group_label>OXi4503 + cytarabine dose escalation</arm_group_label>
    <other_name>CA1P</other_name>
    <other_name>combretastatin A1-diphosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase 2 - OXi4503 + cytarabine</intervention_name>
    <description>Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with AML</description>
    <arm_group_label>Phase 2 AML</arm_group_label>
    <other_name>CA1P</other_name>
    <other_name>combretastatin A1-diphosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase 2 - OXi4503 + cytarabine</intervention_name>
    <description>Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with MDS</description>
    <arm_group_label>Phase 2 MDS</arm_group_label>
    <other_name>CA1P</other_name>
    <other_name>combretastatin A1-diphosphate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide informed consent

          2. ≥ 18 years of age

          3. Phase 1 (dose escalation) subjects must have either:

               -  AML that has failed to achieve complete remission or morphologic complete
                  remission or

               -  MDS - Marrow blasts must be &gt; 5% and disease failed at least 1 prior
                  hypomethylating agent

          4. Phase 2 (expansion) subjects must have either MDS or relapsed/refractory AML

          5. Eastern Cooperative Oncology Group performance status 0, 1, or 2

          6. Total bilirubin ≤ 2

          7. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5
             times upper limit of normal (ULN)

          8. Serum creatinine &lt; 2.5 times ULN

          9. Prothrombin time (PT)/international normalized ratio and (PTT) in normal range ± 25%

         10. Women of child-bearing potential

         11. Males with female partners of child-bearing potential must agree to use
             physician-approved contraceptive methods

        Exclusion Criteria:

          1. Acute promyelocytic leukemia

          2. Absolute peripheral blood myeloblast count greater than 20,000/mm3

          3. Uncontrolled hypertension

          4. History of congenital long QT syndrome or torsades de pointes

          5. Pathologic bradycardia or heart block

          6. Prolonged baseline QTc

          7. Hiistory of ventricular arrhythmia

          8. Myocardial infarction and/or new ST elevation

          9. Any history of hemorrhagic stroke

         10. Symptomatic congestive heart failure

         11. Major hemorrhagic event within 28 days

         12. Suggestive central nervous system involvement with leukemia

         13. Any open wound

         14. Pregnant and nursing subjects are excluded

         15. Treatment with any anticancer therapy

         16. Treatment with colchicine is excluded.

         17. Psychiatric disorders that would interfere with consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rachel Couchenour</last_name>
    <phone>650-635-7000</phone>
  </overall_contact>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruck Habtemariam</last_name>
      <phone>310-794-0242</phone>
      <email>bhabtemariam@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Schiller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Cline, RN</last_name>
      <phone>352-273-6840</phone>
      <email>clcline@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Cogle R Cogle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Dinh</last_name>
      <phone>305-243-9899</phone>
      <email>y.dinh@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Justin Watts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center and Medical Pavilion</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Cairns, MA</last_name>
      <phone>913-945-7547</phone>
      <email>mcairns3@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Tara Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Combretastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

